The Business Research Company’s report on the Hereditary Transthyretin Amyloidosis Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
#How have key drivers contributed to the rapid growth of the hereditary transthyretin amyloidosis market?
The growing geriatric population is expected to propel the growth of the hereditary transthyretin amyloidosis market going forward. The geriatric population refers to individuals aged 65 and older, often requiring specialized healthcare and support due to aging. The geriatric population is growing due to increasing life expectancy driven by advancements in healthcare and living conditions. Hereditary transthyretin amyloidosis (hATTR) significantly impacts the geriatric population by causing progressive neuropathy and cardiomyopathy, leading to increased morbidity in aging individuals. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the US population aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, marking a 47% increase. Therefore, the growing geriatric population is driving the growth of the hereditary transthyretin amyloidosis market.
Access Your Free Sample of the Global Hereditary Transthyretin Amyloidosis Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
How has the hereditary transthyretin amyloidosis market size evolved, and what are the latest forecasts for its expansion?
The hereditary transthyretin amyloidosis market size has grown strongly in recent years. It will grow from $1.36 billion in 2024 to $1.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to the rising incidence of this disorder, an increase in research and development activities, an increasing number of cardiac amyloidosis cases, growing disease awareness, and increasing healthcare infrastructure.
The hereditary transthyretin amyloidosis market size is expected to see strong growth in the next few years. It will grow to $2.14 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to a growing geriatric population, rising disposable incomes, increasing incidence of hereditary transthyretin amyloidosis, a rise in the development of new drugs, and a rise in genetic testing. Major trends in the forecast period include advanced treatment products, advancements in diagnostic techniques, advancements in drug development, demand for effective therapies, and advancements in medical technology.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
Which major companies dominate the hereditary transthyretin amyloidosis market?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
What trends will shape the future of the hereditary angioedema market?
Major companies operating in the hereditary transthyretin amyloidosis market are developing innovative therapeutics, such as RNAi therapeutics, to target and reduce the production of transthyretin (TTR) protein. RNAi therapeutics are a class of drugs that use RNA interference technology to silence specific genes, thereby reducing the production of disease-causing proteins. For instance, in October 2024, Alnylam Pharmaceuticals, Inc., a US-based biopharmaceutical company, submitted a supplemental new drug application (sNDA) to the US FDA for Vutrisiran (AMVUTTRA) as a treatment for transthyretin amyloidosis with cardiomyopathy. This submission underscores its innovative RNAi therapeutic approach, designed to target and reduce transthyretin (TTR) protein, a key factor in disease progression. Vutrisiran’s subcutaneous administration offers a more convenient and patient-friendly dosing regimen compared to traditional intravenous treatments, positioning it as a potentially transformative option for individuals with this serious condition.
Which region dominates the hereditary transthyretin amyloidosis market, and what factors contribute to its leadership?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How is the hereditary transthyretin amyloidosis market segmented, and which segment holds the largest share?
The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003
How is the hereditary transthyretin amyloidosis market defined, and what are its core characteristics?
Hereditary transthyretin amyloidosis is a rare, inherited disorder caused by mutations in the TTR gene, leading to the misfolding and accumulation of transthyretin protein as amyloid deposits in organs. This condition primarily affects the nervous system, heart, and other tissues, causing progressive neuropathy and cardiomyopathy.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
